Cancer Currents: An NCI Cancer Research Blog
A blog featuring news and research updates from the National Cancer Institute. Learn more about Cancer Currents.
-
Gut Microbes May Influence How Well Radiation Therapy Works against CancerNew research suggests that fungi in the gut may affect how tumors respond to cancer treatments. In mice, when bacteria were eliminated with antibiotics, fungi filled the void and impaired the immune response after radiation therapy, the study found.
-
New on NCI’s Websites for September 2021NCI periodically provides updates on new websites and other online content of interest to the cancer community. See selected content that has been added as of September 2021.
-
COVID-19, Vaccines, and the Immune System: Emerging Research from NCI’s SeroNetIn this Q&A, leaders of NCI’s SeroNet program discuss new research findings on the immune response to the virus that causes COVID-19, new variants of the virus, and the COVID-19 vaccines. They also discuss the effects of the vaccines on people with cancer.
-
Physical Activity May Lessen the Effects of Chemo Brain, Study FindsFor women undergoing chemotherapy for breast cancer, meeting the national physical activity guidelines may help alleviate cognitive issues, a new study suggests. The benefits may be even greater for patients who were physically active before treatment.
-
Opioid Use Drops among Cancer Patients at End of LifeAccording to a new study, among people with cancer in the last month of their lives, filled prescriptions for opioids to control pain have dropped and emergency room visits for pain have increased dramatically.
-
FDA Approves Belumosudil to Treat Chronic Graft-Versus-Host DiseaseFDA has approved belumosudil (Rezurock) for the treatment of chronic graft-versus-host disease (GVHD). The approval covers the use of belumosudil for people 12 years and older who have already tried at least two other therapies.
-
Alcohol Tied to 750,000 Cancer Cases Worldwide in 2020Nearly 750,000 cases of cancer diagnosed worldwide in 2020, or 4%, can be attributed to alcohol consumption, according to a new study. While heavy drinking accounted for most cases, light and moderate drinking accounted for a modest amount.
-
New Task Force Focuses on Quality of Life for AYAs with CancerCancer can greatly disrupt life for adolescents and young adults, who are already going through major life changes. Gathering data on how cancer and its treatment affect this age group will improve their quality of life during and beyond treatment.
-
FDA Approval of Rylaze Will Address Drug Shortage for Childhood ALLFDA has approved a new form of asparaginase called Rylaze. The drug was developed to help alleviate shortages of Erwinia asparaginase, a key part of treatment for children and adults with acute lymphoblastic leukemia.
-
Can an Antibiotic Treat Cancers that Become Resistant to PARP Inhibitors?In lab studies, the antibiotic novobiocin showed promise as a treatment for cancers that have become resistant to PARP inhibitors. The drug, which inhibits a protein called DNA polymerase theta, will be tested in NCI-supported clinical trials.
-
Pattern of DNA Damage Links Colorectal Cancer and Diet High in Red MeatResearchers have discovered a consistent pattern of DNA damage in colorectal tumors that may explain how a diet high in red and processed meat can help cause colorectal cancer.
-
Advancing Cancer Prevention: A Conversation with NCI’s Dr. Philip CastleThe director of NCI’s Division of Cancer Prevention, Dr. Philip Castle, discusses the division’s priority areas and his vision for making more rapid progress in cancer prevention, including moving toward precision prevention and immunoprevention.
-
For Kids with Medulloblastoma, Trial Suggests Radiation Can Be TailoredStandard radiation for medulloblastoma can cause long-term damage to a child’s developing brain. A new clinical trial suggests that the volume and dose of radiation could be safely tailored based on genetic features in the patient’s tumor.
-
New on NCI’s Websites for July 2021NCI periodically provides updates on new websites and other online content of interest to the cancer community. See selected content that has been added as of July 2021.
-
Could a Diabetes Diagnosis Help Detect Pancreatic Cancer Early?Numerous studies have pointed to a link between new-onset diabetes and pancreatic cancer. Now, several large NCI-supported studies are testing ways to pick out those people whose diabetes might be a sign of early pancreatic cancer, when treatments may be more effective.
-
For Advanced Prostate Cancer, Radiopharmaceutical Improves SurvivalA drug called Lu177-PSMA-617 may be a new option for treating advanced prostate cancer. In a large clinical trial, adding the drug—a type of radiopharmaceutical—to standard treatments improved how long participants lived.
-
FDA Approval of KRAS Inhibitor Sotorasib for Lung Cancer Hailed as MilestoneFDA has approved the first KRAS-blocking drug, sotorasib (Lumakras). The approval, which covers the use of sotorasib to treat some patients with advanced lung cancer, sets the stage for other KRAS inhibitors already in development, researchers said.
-
Avasopasem Shields Normal Cells from Radiation, Helps Kill Cancer CellsA drug called avasopasem manganese, which has been found to protect normal tissues from radiation therapy, can also make cancer cells more vulnerable to radiation treatment, a new study in mice suggests.
-
Nivolumab and Relatlimab Combination Shows Promise in Advanced MelanomaPeople with advanced melanoma treated with two immunotherapy drugs—nivolumab (Opdivo) and a new drug called relatlimab—lived longer without their cancer getting worse than those treated only with nivolumab, results from a large clinical trial show.
-
Nivolumab-Based Combinations Improve Survival in Advanced Esophageal CancerA treatment regimen that combines the immunotherapy drug nivolumab (Opdivo) with either another immunotherapy drug or chemotherapy may be a new initial treatment option for people with advanced esophageal cancer, a large clinical trial finds.